Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
Part of paid clinical trials in Seattle, Washington.
- Sponsor
- Benaroya Research Institute
- Study ID
- NCT00343044
- Phase
- PHASE2
- Status
- Completed
Conditions
- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cancer
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Topotecan — DRUGTopotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.
- Bevacizumab — DRUGbevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.
Study Details
The purpose of this study is to evaluate the clinical safety and toxicity of intravenous bevacizumab (Days 1 and 15 of a 28 day cycle) in combination with weekly topotecan (Days 1, 8, 15 of a 28 day cycle) in patients with platinum resistant recurrent ovarian, fallopian tube and primary peritoneal cancer.
Key Dates
- First listed
- Jun 22, 2006
- Start date
- Jun 30, 2006
- Status verified
- Apr 2015
- Primary completion
- Jan 31, 2010
- Completion
- Aug 31, 2011
Study Design
- Enrollment
- 40 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: TreatmentSubjects received standard topotecan with the addition of bevacizumab. Cycles were 28 days and continued until toxicity, progression or subject wish to discontinue treatment. Topotecan administered 4 mg/m2 IV on days 1, 8 and 15 and bevacizumab IV 10 mg/kg, days 1 and 15 of each cycle.
Primary Outcome Measure
Progression Free Survival [ Time Frame: PFS and OS were defined as the number of months after commencing study treatment until progressive disease or death. ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Puget Sound Oncology Consortium (PSOC) | Seattle | Washington | 98104 | - |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | - |
Find similar trials in Seattle, WA
By condition
By specialty
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Clinical Pre-screening Protocol for Ovarian CancerRecruiting · Allarity Therapeutics · Boston, Massachusetts
- TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of PreventionRecruiting · University Medical Center Nijmegen · Chicago, Illinois
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California